- PCSK9 Inhibitor Found Effective for Primary Prevention Medscape
- Amgen cholesterol drug cuts risk of first cardiac event by 25% Reuters
- Evolocumab lowers risk for first major cardiovascular events Healio
- Taher Modarressi Highlights VESALIUS Trial as Standout of AHA25 Lipid Session Oncodaily
- PCSK9 inhibitor reduced major CVD events in adults with no prior heart attack or stroke www.heart.org